Barclays initiated coverage on Cytokinetics with a new price target
$CYTK
Biotechnology: Pharmaceutical Preparations
Health Care
Barclays initiated coverage of Cytokinetics with a rating of Overweight and set a new price target of $55.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/24/2025 | $55.00 | Overweight | Barclays |
| 2/7/2025 | $86.00 | Buy | Citigroup |
| 1/22/2025 | $80.00 | Buy | Stifel |
| 11/8/2024 | $80.00 | Outperform | RBC Capital Mkts |
| 8/13/2024 | $85.00 → $60.00 | Buy → Neutral | Goldman |
| 1/24/2024 | $61.00 → $92.00 | Buy → Neutral | UBS |
| 1/5/2024 | $60.00 → $90.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/9/2023 | $50.00 | Buy | Goldman |
4 - CYTOKINETICS INC (0001061983) (Issuer)
4 - CYTOKINETICS INC (0001061983) (Issuer)
4 - CYTOKINETICS INC (0001061983) (Issuer)